Christine’s poster, titled “Can Frequency of Prostate Biopsy on Active Surveillance Be Reduced Without Significantly Increasing Risk?,” was recognized in the “active surveillance” session.

Active surveillance (AS) for prostate cancer (CaP) involves close follow-up with serial prostate biopsies. The optimal biopsy frequency during follow-up has not been determined, resulting in variation in practice. The goal of this investigation was to use longitudinal AS biopsy data to assess if the frequency of biopsy could be reduced without substantially prolonging the time to detection of Gleason ≥ 7 disease. The research highlighted in the poster found that, while annual biopsy for low-risk men on AS is associated with the shortest time to detection of Gleason ≥ 7 disease, several alternative strategies may allow for less frequent biopsy without sizable increases in time to detecting grade progression.